Pfizer Inc. revenue $15.03B, quarter ended Jun 28, 2026
Pfizer Inc. reported $15.03B of revenue in the quarter ended Jun 28, 2026, +2.6% on the quarter ended Jun 29, 2025. Across the six months ended Jun 28, 2026, $29.48B, +3.9% on the six months ended Jun 29, 2025.
Quarterly revenue, quarter ended Jun 28, 2026 $15.03B +2.6% year over year +$381.00M against $14.65B for the quarter ended Jun 29, 2025
Six months ended Jun 28, 2026 $29.48B +3.9% JMM's sum of the 2 contiguous quarters below, 179 days end to end, each one accession-linked. Measured against the $28.37B of the six months ended Jun 29, 2025.
Every PFE quarter JMM stores, on a real time axis
Which quarters built the six months ended Jun 28, 2026, and which carried the change
- Quarter ended Mar 29, 2026 $14.5B against $13.7B for the quarter ended Mar 30, 2025 +$736.0M 66% of the change 10-Q
- Quarter ended Jun 28, 2026 $15.0B against $14.7B for the quarter ended Jun 29, 2025 +$381.0M 34% of the change 10-Q
What the PFE record says, and what to quote from it
Growth is slowing, from +5.4% for the quarter ended Mar 29, 2026 to +2.6%.
The last 5 comparable prints run -7.8%, +10.3%, -5.9%, +5.4%, +2.6%, so the latest rate is 2.8 points below the quarter before it, and the fastest quarter in this run was +10.3% for the period ended Jun 29, 2025. Here is what those points are worth: at +10.3%, the quarter ended Jun 28, 2026 would have printed $16.16B instead of $15.03B. The $1.13B between them is the whole of what decelerating means at this size.
The sequential step, +4.0% from the quarter ended Mar 29, 2026, is mostly this issuer's own seasonality, which is why it is not the headline here and not the headline anywhere serious.
These quarters do not close a fiscal year. SEC builds its quarterly frames from the values a filer tags, and most filers tag no standalone fourth quarter: it is reported inside the annual filing as part of the year. Six months ended Jun 28, 2026 is the largest total they genuinely close, and it is the second figure above. The annual report in PFE's filing history carries the year as Pfizer Inc. reports it.
Is this the same legal entity, and who says so
PFE has filed under one earlier name
| Name on file | From | Until |
|---|---|---|
| PFIZER INC |
From the issuer's own SEC submissions record. The CIK does not change when the name does, so every filing made under a name above sits in the same filing history as the ones made today, and a search for the old name is a search for this company.
PFE quarterly revenue, filing by filing
| Period ended | Quarterly revenue | Year over year | Filed | Evidence |
|---|---|---|---|---|
| 10-Q | $15.0B | +2.6% vs $14.7B, period ended Jun 29, 2025 | Open filing | |
| 10-Q | $14.5B | +5.4% vs $13.7B, period ended Mar 30, 2025 | Open filing | |
| 10-Q | $16.7B | -5.9% vs $17.7B, period ended Sep 29, 2024 | Open filing | |
| 10-Q | $14.7B | +10.3% vs $13.3B, period ended Jun 30, 2024 | Open filing | |
| 10-Q | $13.7B | -7.8% vs $14.9B, period ended Mar 31, 2024 | Open filing | |
| 10-Q | $17.7B | Not stored no quarter one year earlier in the stored set | Open filing | |
| 10-Q | $13.3B | Not stored no quarter one year earlier in the stored set | Open filing | |
| 10-Q | $14.9B | Not stored no quarter one year earlier in the stored set | Open filing |
Every row is the SEC concept Revenues, read from
the SEC company facts API by the JMM collector,
checked Aug 10, 2026. The change column is year over year and names the exact period it was measured
against, because these periods are not contiguous: a change against whichever row happens to sit below would compare
quarters up to three years apart. Earlier rows carry the accession SEC attributes the value to, which can be a later
filing that restated the period, so only the most recent row's 37-day gap is a reporting delay.
PFE against every other Pharmaceutical Preparations filer JMM covers
- JNJ Johnson & JohnsonJNJ $25.3Bperiod ended Jun 28, 2026
- LLY Eli Lilly & CoLLY $23.0Bperiod ended Jun 30, 2026
- ABBV AbbVie Inc.ABBV $17.0Bperiod ended Jun 30, 2026
- PFE Pfizer Inc.PFE, this page $15.0Bperiod ended Jun 28, 2026
- BMY Bristol Myers Squibb Co.BMY $13.0Bperiod ended Jun 30, 2026
- REGN Regeneron Pharmaceuticals, Inc.REGN $4.3Bperiod ended Jun 30, 2026
- TEVA Teva Pharmaceutical Industries Ltd.TEVA $4.1Bperiod ended Jun 30, 2026
- VTRS Viatris IncVTRS $3.7Bperiod ended Jun 30, 2026
- VRTX Vertex Pharmaceuticals Inc. / MAVRTX $3.3Bperiod ended Jun 30, 2026
- JAZZ Jazz Pharmaceuticals plcJAZZ $1.2Bperiod ended Jun 30, 2026
- UTHR United Therapeutics CorpUTHR $783.3Mperiod ended Jun 30, 2026
- RPRX Royalty Pharma plcRPRX $674.1Mperiod ended Jun 30, 2026
- INSM Insmed IncINSM $425.5Mperiod ended Jun 30, 2026
- IONS Ionis Pharmaceuticals Inc.IONS $267.9Mperiod ended Jun 30, 2026
- BBIO BridgeBio Pharma, Inc.BBIO $243.7Mperiod ended Jun 30, 2026
- ROIV Roivant Sciences Ltd.ROIV $1.4Mperiod ended Jun 30, 2026
Each issuer's latest stored quarter, in USD, for every filer JMM covers under SEC SIC 2834. Fiscal calendars differ, so these periods end on different dates: the bars compare scale, not a shared quarter. Coverage is JMM's, not the classification's, so this is not the whole industry.
Continue from the Pfizer Inc. record
Reproduce any row in the table below from the raw XBRL frames, period by period.
CalculatorAnnualize the growth between any two of these quartersPaste a starting and ending value from the table to get a compound annual rate, before and after CPI-U inflation.
GuideWhat the XBRL tag behind this figure actually measuresWhy two issuers reporting the same business can carry different revenue concepts, and what that changes about comparing them.